scholarly journals A pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma

Rare Tumors ◽  
2011 ◽  
Vol 3 (3) ◽  
pp. 95-97
Author(s):  
Vasileios Sakalis ◽  
Anastasia Gkotsi ◽  
Efrosyni Mylonaki ◽  
Aphroditi Pantzaki ◽  
Stavros Charalambous ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Medical Literature ◽  
Recent Literature ◽  
Bladder Tumour ◽  
Local Relapse ◽  
Small Cell ◽  
Prostatic Adenocarcinoma ◽  
Bladder Tumors ◽  
Luteinizing Hormone Releasing Hormone

Small cell carcinoma (SCC) or microcytic carcinoma of the urinary bladder is a rare entity comprising approximately 0.5% of all bladder tumors. Due to its rarity, no prospective studies evaluating the most effective treatment have been published in the medical literature. Several cases of bladder SCC have been presented so far. We describe our case report and we revise the recent literature. Our patient was diagnosed with pure bladder SCC and prostatic adenocarcinoma. After the initial and complete transurethral resection of the bladder tumour (TUR-BT), he underwent a thorax and mediastinum computer tomography (CT) examination to exclude primary pulmonary small cell carcinoma and a bone scan scintigraphy for staging purposes. He received a three 14-day cycles of Cisplatin-containing chemotherapeutic schema and a single dose of Luteinizing-Hormone Releasing hormone (LHRH) analogue injection after 14 days of bicalutamide administration. The patient is followed for 24 months without any signs of bladder SCC recurrence or biochemical or local relapse from prostatic adenocarcinoma.

scholarly journals Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

2012 ◽  
Vol 5 (1) ◽  
pp. 53-56 ◽  
Author(s):  
AKIRA KOMIYA ◽  
KENJI YASUDA ◽  
TETSUO NOZAKI ◽  
YASUYOSHI FUJIUCHI ◽  
SHIN-ICHI HAYASHI ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
High Dose Rate ◽  
Small Cell ◽  
Prostatic Adenocarcinoma ◽  
Low Risk ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Carcinoma Of The Prostate

scholarly journals Histologic variants of acinar prostate carcinomas: Clinicopathologic importance

2020 ◽  
pp. 36-46
Author(s):  
Harmanjot Singh ◽  
Ziad M. El-Zaatari ◽  
Jae Y. Ro
Keyword(s):  
Cell Carcinoma ◽  
Giant Cell ◽  
Small Cell Carcinoma ◽  
Gleason Score ◽  
De Novo ◽  
Small Cell ◽  
Prostatic Adenocarcinoma ◽  
Low Grade ◽  
Signet Ring ◽  
Acinar Carcinoma

Acinar carcinoma comprises more than 90% of prostatic adenocarcinomas and is characterized by a small gland proliferation with an infiltrative growth pattern. The numerous, variably-defined histological variants of prostatic adenocarcinoma can prove to be diagnostic challenges and show prognostic differences when compared to the usual acinar carcinoma, thus emphasizing the importance in accurate recognition. Variants of acinar prostatic adenocarcinoma include the atrophic, pseudohyperplastic, microcystic, foamy gland, mucinous (colloid), signet ring-like cell, pleomorphic giant cell, and sarcomatoid variants. The atrophic, pseudohyperplastic, microcystic, and foamy gland variants can be challenging to diagnose due to their deceptively benign appearance. While the atrophic, pseudohyperplastic, microcystic, and foamy gland variants usually present as low-grade malignancies (Gleason score 6-7), the mucinous (colloid), signet ring-like cell, pleomorphic giant cell, and sarcomatoid variants often present as high-grade malignancies (Gleason score >7) and are usually associated with a worse prognosis. Small cell carcinoma is not considered as a variant of acinar carcinoma, is classified under neuroendocrine tumors, and is recommended not to be assigned a Gleason score. Small cell carcinoma is often preceded by a diagnosis of acinar adenocarcinoma, rarely presents as a de novo tumor, and, as in other organs systems has an aggressive clinical course. In this review article, we discuss variants of prostatic acinar carcinomas and briefly discuss small cell carcinoma. Awareness of variants of acinar prostate carcinoma and their clinicopathologic features is essential to rendering an accurate diagnosis and clinical management of patients with these tumors.

Malignancies Arising in Oncocytic Schneiderian Papillomas

2001 ◽  
Vol 125 (10) ◽  
pp. 1365-1367 ◽  
Author(s):  
Anirban Maitra ◽  
Leland B. Baskin ◽  
Edward L. Lee
Keyword(s):  
Cell Carcinoma ◽  
Malignant Transformation ◽  
Small Cell Carcinoma ◽  
Medical Literature ◽  
Benign Neoplasm ◽  
Undifferentiated Carcinoma ◽  
Small Cell ◽  
Benign Neoplasms ◽  
Sinonasal Undifferentiated Carcinoma

Abstract Oncocytic schneiderian papillomas (OSPs) are uncommon benign neoplasms that arise from the sinonasal schneiderian epithelium. Malignancies arising in OSPs are rare, and, to our knowledge, only 14 such instances have been reported in the medical literature. We report 2 additional cases—a small cell carcinoma and a sinonasal undifferentiated carcinoma arising in OSPs and presenting synchronously with the benign neoplasm. The potential for malignant transformation in OSPs is small, but warrants that these papillomas be completely excised to exclude a coexisting carcinoma.

scholarly journals The oncological outcomes of small cell carcinoma of the bladder

2018 ◽  
Vol 13 (8) ◽  
Author(s):  
Harley A. Williams ◽  
Nahid Punjani ◽  
Obaidullah Khan ◽  
Nicholas E. Power
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Treatment Guidelines ◽  
Bladder Tumour ◽  
Outcome Data ◽  
Small Cell ◽  
Smoking History ◽  
Charlson Comorbidity Index Score ◽  
Depth Analysis ◽  
Carcinoma Of The Bladder

Introduction: Small cell carcinoma of the bladder (SmCC) is a rare and aggressive genitourinary malignancy. The paucity of clinical trials and outcome data provide no standard treatment guidelines. Accordingly, patient prognosis is poor. Our goal was to present the first comprehensive in-depth analysis of SmCC in a tertiary Canadian centre. Methods: We retrospectively reviewed all patients diagnosed with primary SmCC at the London Regional Cancer Program between January 1990 and 2016. The primary outcome was overall survival (OS). We examined a number of secondary outcomes and baseline characteristics. Results: We identified 15 men and six women (median age 72 years) with a SmCC diagnosis (median followup 11.33 months). Median Charlson Comorbidity Index score was 7 (interquartile range [IQR] 5‒10) and 15 patients had a smoking history. Most common presentation was gross hematuria (18 patients, 86%), and pT2 stage at transurethral resection of the bladder tumour (TURBT) (n= 7/21, 33%), although five patients had cT4 (24%). Pure SmCC was found in nine individuals (43%), whereas 12 had mixed differentiation (57%). From initial staging, 15 patients had extravesical disease (71%), 10 had positive pelvic lymphadenopathy (48%), and distant metastases occurred in six (29%). In our series, five individuals (24%) underwent cystectomy, 18 (86%) received radiation, and 14 (67%) received adjuvant chemotherapy. The median OS was 15 months (two-year OS was 19%). Conclusions: SmCC is a rare and aggressive form of bladder cancer. Despite multimodal therapy, prognosis remains guarded, with little improvement seen over the study’s 25-year duration. An understanding of study limitations is warranted in interpretation of results.

A Case of Small Cell Carcinoma of the Supraglottis

2010 ◽  
Vol 53 (12) ◽  
pp. 784
Author(s):  
Jong Chul Hong ◽  
Seo Hee Rha ◽  
Hyun-Jik Lee ◽  
Heon Soo Park
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell
Sign in / Sign up

Export Citation Format

Share Document